Shein Hong Kong IPO to Raise $1.7 Billion at $26.5 Billion Valuation 
Nvidia Options Price in $280 Billion Earnings Swing 
OpenAI Data Center Chief Chris Malone Exits Ahead of Planned 2027 Listing 
SK Hynix Shares Fall as Workers Reject Wage Deal 
Luxshare Shares Rise as First-Half Profit Jumps 18% 
Meta Agrees to $18 Billion Settlement, Tightens Teen Social Media Rules 
Woodside Drops $5 Billion Clean Energy Plan as Profit Rises 7% 
Salesforce Shares Surge as AI Demand Powers Q2 Earnings Beat 
HP Stock Drops 9% Despite Q3 Earnings Beat and Raised 2026 Outlook 
Adidas, Puma Shares Fall as Dick’s Sporting Goods Cuts Outlook 
BofA Names ASML Top Semiconductor Equipment Pick on Growth, Valuation 
Australia’s Big Four Banks Face Mortgage Slowdown as Valuations Draw Scrutiny 
Nvidia Reportedly Eyes $13 Billion Hugging Face Acquisition 
SK Biopharmaceuticals Secures Global Rights to Biohaven Epilepsy Drug Opakalim 
Tesla Raises Cybertruck Prices by $5,000 in US 
Google Expands Gemini Enterprise With AI Tools for Legal Sector 
Add as a preferred source on Google
WAYNE, Pa., April 24, 2018 -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led biopharmaceutical company committed to identifying, developing, and commercializing innovative therapies to address significant unmet needs in aesthetic and medical dermatology and immunology, will report financial results for first quarter 2018 on Tuesday, May 8, 2018 after U.S. financial markets close.
Management will conduct a conference call at 5:00 PM ET that day to discuss the Company’s financial results and provide a general business update. A live webcast of the event can be accessed on the Events and Presentations page on the Investors section of the Aclaris website at http://www.aclaristx.com/events-and-webcasts. A replay of the webcast will be archived on the Aclaris website following the event.
To participate on the live call, please dial (844) 776-7782 (domestic) or (661) 378-9535 (international), and reference conference ID 7386579 prior to the start of the call.
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc. is a dermatologist-led biopharmaceutical company committed to identifying, developing, and commercializing innovative therapies to address significant unmet needs in dermatology, both aesthetic and medical, and immunology. Aclaris’ focus on market segments with no FDA-approved medications or where treatment gaps exist has resulted in the first FDA-approved treatment for raised seborrheic keratoses and several clinical programs to develop medications for the potential treatment of common warts, alopecia areata, and vitiligo. For additional information, please visit www.aclaristx.com and follow Aclaris on LinkedIn.
Contact:
Aclaris Contact
Michael Tung, M.D.
Senior Vice President
Corporate Strategy/Investor Relations
484-329-2140
[email protected]
